Tuesday May 14
Edwards Lifesciences Up 6% After Share Repurchase, Insider Buying Announced
Shares of Edwards Lifesciences are among the biggest gainers on the Standard & Poor's 500 index today, boosted after the company announced a $750 million share buyback program .
Wed May 08, 2013
Edwards Lifesciences to Present at the Bank of America Merrill Lynch 2013 Healthcare Conference
Larry L. Wood, Edwards Lifesciences' Corporate Vice President, Transcatheter Heart Valves, is scheduled to speak to conference attendees at 10:00 a.m. PT .
Tue May 07, 2013
Edwards Lifesciences Price Target Cut to $64.00 by Analysts at JP Morgan Cazenove
The firm currently has a "neutral" rating on the stock. Other equities research analysts have also recently issued reports about the stock.
Fri May 03, 2013
Insider Buys at 52-Week Lows
Several insiders made buys this week as the price of their companies hit or neared 52-week low prices.
Mon Apr 29, 2013
A Board Member Bought Shares of Edwards Lifesciences Corp
A Form 4 filed with the SEC has disclosed that Wesley von Schack, a member of the Board of Directors at Edwards Lifesciences Corp , directly acquired 2,000 shares on April 26th at an average price of $64.95 per share.
Sun Apr 28, 2013
Edwards Lifesciences Price Target Cut to $64.00
The firm currently has a "sell" rating on the stock. A number of other firms have also recently commented on EW.
Sat Apr 27, 2013
Edwards Lifesciences PT Raised to $80.00
The firm currently has a "buy" rating on the stock. EW has been the subject of a number of other recent research reports.
Thu Apr 25, 2013
Edwards CEO Sold Stock 2 Weeks Before It Tanked
Earlier this week the stock of Edwards Lifesciences tanked after the company announced weak Sapien sales and lowered its sales guidance for the rest of the year.
Medical Technology Industry Reports Insider Sells at 52-Week Lows
This week brought about several 52-week low prices in the technology sector of the market.
Wed Apr 24, 2013
Edwards Lifesciences Price Target Lowered to $68.00 at JP Morgan Cazenove
The firm currently has a "neutral" rating on the stock. Several other analysts have also recently commented on the stock.
Edwards Lifesciences's Neutral Rating Reaffirmed at Zacks
's stock had its "neutral" rating reaffirmed by Zacks in a research note issued on Wednesday, AnalystRatings.Net reports.
Medical Device/Diagnostic Ind.
Edwards Lifesciences' Projection of TAVR Adoption Rates in U.S. Turns Out To Be Too Rosy
Medtronic is not too far behind, although it has been hobbled by a slow-enrolling pivotal trial that finally closed in early January.
Tue Apr 23, 2013
Medical Device/Diagnostic Ind.
Despite Sales Disappointments, Edwards Still Sees Long-Term Wins
The technology leader in transcatheter heart valves seems to be stalling when it comes to product adoption - at least in the short term.
Edwards Lifesciences (EW) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS
Edwards Lifesciences announced its earnings results on Tuesday. The company reported $0.72 earnings per share for the quarter, missing the analysts' consensus estimate of $0.76 by $0.04, StockRatingsNetwork reports.